Olga Burdaeva

5.3k total citations · 2 hit papers
27 papers, 2.1k citations indexed

About

Olga Burdaeva is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Olga Burdaeva has authored 27 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Olga Burdaeva's work include Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Olga Burdaeva is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Treatment and Pharmacology (9 papers). Olga Burdaeva collaborates with scholars based in Russia, United States and Germany. Olga Burdaeva's co-authors include George W. Sledge, Martin Frenzel, Masakazu Toi, Norikazu Masuda, Xavier Pivot, Han Koh, Meena Okera, Susana Barriga, Joohyuk Sohn and Eva‐Maria Grischke and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Olga Burdaeva

27 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations George W. Sledge, Masakazu Toi et al. JAMA Oncology profile →

Peers

Countries citing papers authored by Olga Burdaeva

Since Specialization

Citations

This map shows the geographic impact of Olga Burdaeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Burdaeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Burdaeva more than expected).

Fields of papers citing papers by Olga Burdaeva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Burdaeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Burdaeva. The network helps show where Olga Burdaeva may publish in the future.

Co-authorship network of co-authors of Olga Burdaeva

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Burdaeva. A scholar is included among the top collaborators of Olga Burdaeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Burdaeva. Olga Burdaeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial 2023 ·Supportive Care in Cancer ·John A. Glaspy, Igor Bondarenko, Olga Burdaeva, Jianmin Chen, Dean Rutty, (unknown), (unknown), (unknown), Simon Li	3
2	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer 2021 ·Clinical Cancer Research ·Patrick Neven, Stephen Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Yi Lu, Nadine Haddad, Karla Hurt, Antonio Llombart‐Cussac, George W. Sledge	7
3	Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab 2020 ·BMC Cancer ·(unknown), (unknown), Guzel Mukhametshina, (unknown), Olga Burdaeva, (unknown), (unknown), Kirti Srivastava, (unknown), (unknown), (unknown), (unknown), Roman Ivanov	16
4	Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE 2020 ·Journal of Clinical Oncology ·Stephen Johnston, Roberto Hegg, Seock‐Ah Im, In Hae Park, Olga Burdaeva, G. Kurteva, Michael F. Press, Sergei Tjulandin, Hiroji Iwata, Sérgio D. Simon, Sarah Kenny, Séverine Sarp, Miguel Izquierdo, Lisa S. Williams, William J. Gradishar	82
5	MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer. 2020 ·Journal of Clinical Oncology ·Patrick Neven, Stephen Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Yi Lu, Nadine Haddad, Karla Hurt, Peter A. Kaufman, Antonio Llombart‐Cussac, George W. Sledge	2
6	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer 2019 ·Lung Cancer ·Daniel Morgensztern, Nina Karaseva, Enriqueta Felip, Ignacio Delgado, Olga Burdaeva, Manuel Dómine, Primo N. Lara, Paul K. Paik, Ulrik Lassen, С. В. Орлов, José Trigo, (unknown), Katherine L. Baker-Neblett, (unknown), Xiaowei Wang, Yan Li, Ionel Mitrica, M. Phillip DeYoung, Pilar Garrido	19
7	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 breakdown → 2019 ·JAMA Oncology ·George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Pierfranco Conté, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac	590
8	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy breakdown → 2017 ·Journal of Clinical Oncology ·George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Antonio Llombart‐Cussac	1103
9	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results. 2017 ·Journal of Clinical Oncology ·Wolfgang Janni, Howard A. Burris, Kimberly Blackwell, Lowell L. Hart, Arlene Chan, Arnd Nusch, Olga Burdaeva, Emilio Alba, Denise A. Yardley, Thomas Bachelot, Miguel Gil‐Gil, Donald Richards, Joseph A. Sparano, Joseph Kattan, Hugues Bourgeois, (unknown), Bhuvaneswari Ramaswamy, Santosh Sutradhar, (unknown), Pierfranco Conté	5
10	MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy 2017 ·Journal of Clinical Oncology ·George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Antonio Llombart‐Cussac	10
11	Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC 2016 ·Annals of Oncology ·(unknown), Olga Burdaeva, (unknown), (unknown), (unknown), Guzel Mukhametshina, (unknown), Roman Ivanov	7
12	Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study. 2016 ·Journal of Clinical Oncology ·Firas Badin, Anne C. Chiang, William B. Fisher, Sergey Orlov, Harry Harper, (unknown), Wael A. Harb, Ebenezer A. Kio, Priya Gopalan, Daniel Haggstrom, Olga Burdaeva, Anita Zahlten‐Kumeli, Sanjay Aggarwal, Mihaela Obreja, Vera Gorbunova	2
13	Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study. 2015 ·Journal of Clinical Oncology ·(unknown), Marina Nechaeva, Olga Burdaeva, Vladimir Vladimirov, Igor Lifirenko, Н. В. Коваленко, М. В. Копп, Marina Matrosova, (unknown), (unknown), Pavel Skopin, Daniil Stroyakovskiy, Petr Krivorotko, (unknown), (unknown), (unknown), (unknown), Roman Ivanov, Sergei Tjulandin	5
14	A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015) 2014 ·Journal of Thoracic Oncology ·Tony Mok, В. А. Горбунова, Erzsébet Juhász, (unknown), Olga Burdaeva, С. В. Орлов, Chong‐Jen Yu, Venice Archer, Magalie Hilton, Paul Delmar, Céline Pallaud, Martin Reck	39
15	Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer 2014 ·Lung Cancer ·Céline Pallaud, Martin Reck, Erzsébet Juhász, (unknown), Chong‐Jen Yu, Olga Burdaeva, С. В. Орлов, Magalie Hilton, Venice Archer, Tony Mok	14
16	Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients. 2014 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Olga Burdaeva, (unknown), М. В. Копп, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Roman Ivanov, (unknown), Sergei Tjulandin	11
17	Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients. 2014 ·Journal of Clinical Oncology ·Sergey Orlov, Olga Burdaeva, (unknown), М. В. Копп, (unknown), (unknown), Oleg Gladkov, (unknown), (unknown), (unknown), (unknown), Н. В. Коваленко, (unknown), (unknown), Roman Ivanov, (unknown), Sergei Tjulandin	11
18	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial 2013 ·Clinical Cancer Research ·Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, (unknown), Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, (unknown), Vanessa Potter, (unknown), Nathalie A. Lokker, Peter J. O’Dwyer	69
19	Eniluracil Plus 5-Fluorouracil and Leucovorin: Treatment for Metastatic Breast Cancer Patients in Whom Capecitabine Treatment Rapidly Failed 2013 ·Clinical Breast Cancer ·Edgardo Rivera, Jenny C. Chang, Semiglazov Vf, Olga Burdaeva, Mary Kirby, Thomas Spector	7
20	9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC) 2011 ·European Journal of Cancer ·Tony Mok, В. А. Горбунова, (unknown), (unknown), Olga Burdaeva, Cunjing Yu, Paul Delmar, Céline Pallaud, Maud Jonnaert, Martin Reck	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact